Abstracts

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

#	Title	Authors	Category	Keywords
O8	The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment.	Elizabeth R. Stirling, MS; Adam Wilson; Mitra Kooshki; Lilya Yamaleyeva; Guanxu Jin; Wei Zhang; Lance D. Miller, MS, PhD; Pierre L. Triozzi, MD; David R. Soto-Pantoja, PhD;	Cellular Therapies	Biomarkers; Checkpoint blockade; Metabolism; Tumor microenvironment
O49	Chronic activation under hypoxia drives T cell differentiation to exhaustion	Nicole E. Scharping, PhD; Yiyang Wang, N/A; Ashley Menk, MS; Greg M. Delgoffe, PhD;	Immune Cell Biology	Checkpoint blockade; Coinhibition; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
O51	Sirt2 inhibition enhances anti-tumor immunity by promoting T cell metabolism	Imene Hamaidi, PhD; Lin Zhang, MD. Ph.D; Nayoung Kim, Ph.D; Min-Hsuan Wang; Cristina Iclozan, PhD; Bin Fang, PhD; Min Liu, PhD; John Koomen, PhD; Anders E. Berglund, PhD; Sean J. Yoder; Jiqiang Yao, PhD; Ben C. Creelan, MD, MS; Scott J. Antonia, MD. PhD; Sungjune Kim, MD PhD;	Immune Cell Biology	Checkpoint blockade; Clinical trial; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
O73	Designed improvement to T-cell immunotherapy by integrated single cell profiling.	Irfan N. Bandey, PhD; Jay RT. Adolacion, PhD; Gabrielle Romain, PhD; Melisa Martinez, PhD; An Xingyue, PhD; Arash Saeedi; Rasindu Rajanayke; Ivan Liadi, PhD; Harjeet Singh, PhD; Laurence JN. Cooper, MD, PhD; Navin Varadarajan, PhD;	Other	Antibody; Bioinformatics; Biomarkers; Chemokine; Costimulation; Gene expression; Immune suppression; Leukemia/Lymphoma; Metabolism; Proteomics
P116	Centrifuge-free red blood cell lysis and immunostaining of whole blood for flow cytometry using Laminar Wash™ system	Ira Kim; Melvin Lye; Chyan Ying Ke; Nadiezda Fernandez Oropeza; Sigeeta Rajaram; Kong Leong Cheng; Ih Chin Kon; Royce Pek; Namyong Kim, PhD;	Biomarkers, Immune Monitoring, and Novel Technologies	Biomarkers; Immune suppression; Metabolism; NK/NK T cell; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs)
P158	Suboptimal ER stress Induced Autophagy Regulates Anti-Tumor T Cell Response	Shilpak Chatterjee; Danh T. Tran; Kim Dosung; Satish N. Nadig; Carl Atkinson; Hongjun Wang; J. Alan Dieh; Shikhar Mehrotra, PhD; Paramita Chakraborty, PhD;	Cellular Therapies	Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs)
P160	Engineered natural killer cells redirected against adenosinergic immunometabolic suppression for the immunotherapy of lung carcinoma	Andrea Chambers, MS; Kyle B. Lupo, BS; Jiao Wang, PhD; Sandro Matosevic, PhD;	Cellular Therapies	Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; NK/NK T cell; Solid tumors; Targeted therapy; Tumor microenvironment
P181	Multi-phenotype CRISPR-Cas9 screens identify p38 kinase as a target for adoptive immunotherapies	Devikala Gurusamy, PhD; Suman Vodnala; Amanda Henning; Rigel Kishton; Tori N. Yamamoto; Arash Eidizadeh; Li Jia; Christine M. Kariya; Mary Black; Robert L. Eil; Douglas Palmer; Zhiya Yu; Jenny Pan, MD; Madhusudhanan Sukumar; Shashank J. Patel; Nicholas P. Restifo, MD;	Cellular Therapies	Adoptive immunotherapy; Bioinformatics; CAR T cells; Leukemia/Lymphoma; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor antigens
P184	Activating marrow infiltrating lymphocytes in hypoxia enhances their efficacy in adoptive T-cell therapy	Megan K. Heimann, PhD candidate; Ervin Griffin; Luca Biavati, MD; Amy Thomas; Danielle Dillard; Elizabeth Zawidzka; Brianna Richardson; Robert D. Leone; Gregory Szeto; Kimberly A. Noonan, PhD; Ivan M. Borrello, MD;	Cellular Therapies	Adoptive immunotherapy; Cytokine; Gene expression; Metabolism; T cell; Tumor antigens; Tumor microenvironment
P227	Co-expression of the metabolic enzyme GOT2 with a GPC3-targeted CAR-T overcomes challenges of the solid tumor microenvironment, substantially improving therapeutic efficacy in solid tumor xenografts	Kathleen R. Whiteman, MS; Kathleen R. Whiteman, MS; Tapasya Pai; Eugene Choi; Taylor Hickman; Tyler Johnson; Luke Barron, PhD; Taylor Friedman; Madaline Gilbert; Binzhang Shen; Seth Ettenberg; Kathleen McGinness; Greg Motz;	Cellular Therapies	Adoptive immunotherapy; CAR T cells; Metabolism; Solid tumors; T cell; Tumor microenvironment
P259	Hydrogel-enabled Intratumoral Co-Delivery of Anti-PD-1 Antibody and Adenosine Deaminase in a Mouse Model of Renal Cell Carcinoma	Ngoc B. Pham, BS; Ketki Velankar, MS; Ngoc B. Pham, BS; Wilson Meng, PhD; Ellen S. Gawalt; Nathan R. Schueller;	Checkpoint Blockade Therapy	Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P311	Dual antagonism of prostaglandin receptors EP2 and EP4 by TPST-1495 suppresses tumor growth and stimulates anti-tumor immunity	Chan C. Whiting, PhD; Kim Fischer, PhD; Bryan Laffitte, PhD; Lisa Rahbaek, PhD; Nick Stock, PhD; Davorka Messmer, PhD; Austin Chen, PhD; Traci Olafson; Natalie Nguyen; Amanda Enstrom, PhD; Derek Metzger; Brian Francica; Dingzhi Wang, PhD; Raymond Dubois, PhD, MD; Ginna G. Laport, MD; Peppi Prasit, PhD; Thomas W. Dubensky, Jr., PhD;	Checkpoint Blockade Therapy	Checkpoint blockade; Dendritic cell; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P440	Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (PPARα) Antagonist as a Single Agent (SA) or in Combination in Subjects with Advanced Cancers	John D. Powderly, II, MD, CPI; Saurin Chokshi, MD; Johanna Bendell, MD; Leisha A. Emens, MD, PhD; Jason J. Luke, MD, FACP; Brian Francica; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD; Ginna G. Laport, MD;	Clinical Trial In Progress	Checkpoint blockade; Clinical study; Clinical trial; Metabolism; Solid tumors; Tumor microenvironment
P468	Targeting the ICOS pathway in combination with chemotherapy to enhance T-cell mediated anti-tumor immune responses	Tamer Mahmoud, PhD; Jeffrey M. Riggs; Madhu Ramaswamy, PhD; Leigh Hostetler; Brian Naiman; Ilyssa Ramos; Sean Turman; Fernanda Pilataxi; Christopher A. Morehouse, MD; Alex Alfaro; Norman Peterson; Ryan Fleming; Nazzareno Dimasi; Kyle Kuszpit; Ronald Herbst; Gianluca Carlesso, PhD;	Combination Immunotherapies	Antibody; Chemotherapy; Costimulation; Metabolism; Regulatory T cell (Treg cell); Solid tumors; T cell
P497	DRP-104, A Novel Broad Acting Glutamine Antagonist, Induces Distinctive Immune Modulation Mechanisms and Synergistic Efficacy in Combination with Immune Checkpoint Blockade	Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD;	Combination Immunotherapies	Checkpoint blockade; Monocyte/Macrophage; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P501	Dietary deprivation of non-essential amino acids improves anti-PD-1 immunotherapy in murine colon cancer	Xiyan Li, PhD; Zehui Li, PhD; Grace X. Yang, PhD; Shuang Zhou, PhD; Xin Wang, MD, PhD; Xiyan Li, PhD;	Combination Immunotherapies	Metabolism; Solid tumors
P522	Preclinical development of M4112, an IDO1/TDO2 dual selective and orally bioavailable small molecule inhibitor, and combination with avelumab, for treatment of solid tumors	Jieqing Chen, MD; Chia Lin Chu, PhD; Feng Jiang, PhD; Chunxiao Xu, PhD; Yanping Zhang; Sireesha Yalavarthi; Molly Coop; Hong Wang; Yanyan Wang; Bettina Hanschke; Anindya Siddharta; Sen Zhang; Amit Deshpande; Bartholomew Naughton, PhD; Filippos Porichis; Tai-An Lin, PhD; Joern-Peter Halle; Tilo Senger; Brian Sherer; Jacques Moisan;	Combination Immunotherapies	Checkpoint blockade; Coinhibition; Immune suppression; Metabolism; Solid tumors; Tumor evasion; Tumor microenvironment
P530	Blockade of IDO/TDO downstream effectors restricts a Treg-macrophage suppressive axis and resistance to anti-PD-1 therapy	Luis F. Campesato, PhD; Sadna Budhu, PhD; Jeremy H. Tchaicha, PhD; Mathieu Gigoux, PhD; Ivan Cohen; Levi M. Mangarin, BS; David Redmond; Stephane Pourpe; Cailian Liu, MD; Roberta Zappasodi, PhD; Dmitriy Zamarin, MD, PhD; Mark Manfredi, PhD; Karen McGovern, PhD; Taha Merghoub, PhD; Jedd D. Wolchok, MD, PhD; Luis F. Campesato, PhD;	Combination Immunotherapies	Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Metabolism; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P568	Terminally exhausted CD8+ T cells potentiate the tolerogenic tumor microenvironment as functional suppressors	Paolo DA. Vignali, BA; McLane Watson, BS; Ashley Menk, MS; Nicole E. Scharping, PhD; Kristin DePeaux, BS; Greg M. Delgoffe, PhD;	Immune Cell Biology	Immune suppression; Metabolism; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P572	IFNgamma-induced Nitric Oxide Cell Death is Inhibited by L-arginine Depletion in Renal Cell Carcinoma.	Arnold H. Zea, PhD; Charity F. Silvester, MD Student; Paula Datri, BS; Arnold H. Zea, PhD;	Immune Cell Biology	Costimulation; Cytokine; Immune monitoring; Immune suppression; Immune toxicity; Metabolism; Solid tumors; Targeted therapy; Tumor evasion; Tumor microenvironment
P574	Remodeling Translation Primes CD8+ T Cell Anti-Tumor Immunity	Jessica E. Thaxton, PhD, MSCR; Kiley A. Lawrence; Katie E. Hurst; Lauren Ball, PhD; Lee Leddy, MD, MsCR; Dongjun Chung, PhD;	Immune Cell Biology	Adoptive immunotherapy; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P575	Targeting the Stress Response Kinase GCN2 to Restore Immunity in the Tumor Microenvironment	Lisa A. Marshall, M.S.; Buvana Ravashankar; Lavanya Adysumilli; Deepika Kaveri; Deepa Pookot; Thant Zaw; Raashi Sreenivasan; Mikhail Zibinsky; Jeffrey Jackson; Grant Shibuya; Paul Leger; Anqi Ma; Anton Shakhmin; Andrew Ng; Omar Robles; Oezcan Talay; Delia Bradford; Christophe Colas; Scott Jacobson; Jerick Sanchez; Justy Guagua; Steve Wong; Martin Brovarney; Angela Wadsworth; Goerge Katibah; Gene Cutler; David Wustrow; Paul Kassner; Dirk Brockstedt; Lisa A. Marshall, M.S.	Immune Cell Biology	Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P628	Inhibition of histone deacetylase enhances CD8 T-cell functionality and metabolic fitness resulting in strong anti-tumor response.	Pankaj Gaur, PhD; Vivek Verma, PhD; Rahul Nnadre; Fatmah Alolaqi; Peter Ordentlich, PhD; Lei Wang, PhD; Seema Gupta, PhD; Samir N. Khleif, MD;	Immune-stimulants and immune modulators	Gene expression; Metabolism; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment; Vaccine
P633	BPM31510, a Metabolic Modulating Anti-Cancer Agent, Demonstrates Immune Potentiating Properties by Promoting Cytotoxic T Cells and Reversing Indices of Exhaustion and Immunosuppression	Maria-Dorothea Nastke, PhD; Maria-Dorothea Nastke, PhD; Shiva Kazerounian, PhD; Anne R. Diers, PhD; Stephane Gesta, PhD; Vivek Vishnudas, PhD; Niven R. Narain, PhD; Rangaprasad Sarangarajan, PhD;	Immune-stimulants and immune modulators	Checkpoint blockade; Cytokine; Immune adjuvant; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P655	EOS100850, an A2A receptor antagonist demonstrates efficacy in murine syngeneic tumor models regardless of adenosine concentrations	Romain Pirson, MSc; Anne Catherine Michaux; Diane Jamart; Julie Preillon, MSc.; Lucas Chaible; Chiara Martinoli, PhD; Gregory Driessens, PhD; Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD;	Immune-stimulants and immune modulators	Chemotherapy; Immune suppression; Immune tolerance; Metabolism; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment
P745	Tumor cell metabolism as a barrier to immunotherapy in melanoma	Ashley Menk, MS; Greg M. Delgoffe, PhD; Yana G. Najjar, MD; Ashley Menk, MS; John M. Kirkwood, MD;	Microbiome and other environmental factors	Adoptive immunotherapy; Checkpoint blockade; Metabolism; Tumor microenvironment
P746	Global metabolomics of advanced gastric cancer patients identifies signatures associated with response and clinical benefit from nivolumab	Carrie B. Brachmann, PhD; Daniel Cooper; Kari Wong; Ethan Grant; Daniel V. Catenacci, MD; David Cunningham; Jean-Philippe Metges; Eric Van Cutsem, MD, PhD; Zev Wainberg, MD; Dung Thai; Pankaj Bhargava; Emon Elboudwarej; Ondrej Podlaha; Wadud Khan; Jennifer A. Wargo, MD, MMSc; Manish Shah, MD;	Microbiome and other environmental factors	Bioinformatics; Biomarkers; Checkpoint blockade; Clinical trial; Metabolism; Microbiome; Solid tumors
P751	A targeted next generation sequencing assay to analyze and characterize the gut microbiome for health research	Anna McGeachy, PhD; David Merrill; Shrutii Sarda; Birgit Drews; Wing Lee; Heesun Shin; Janice Au-Young; Rajesh K. Gottimukkala, MS; Aren Ewing; Fiona Hyland;	Microbiome and other environmental factors	Autoimmunity; Bioinformatics; Biomarkers; Carcinogenesis; Checkpoint blockade; Immune monitoring; Inflammation; Metabolism; Microbiome
P769	Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+ T cells, NK cells, and CD103+ dendritic cells in the mouse syngeneic MC38-OVA tumor model	Aatman S. Doshi, MS; Susan Cantin; Michael Secinaro; Yanjun Wang; Laura Prickett; Sharon Tentarelli; Scott Mlynarski; Eric Gangl; M. Raymond V. Finlay; Wenlin Shao, PhD; Alwin Schuller;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; Myeloid cells; Metabolism; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P791	Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)	Andy MacKinnon, PhD; Deepthi Bhupathi, MS; Jason Chen; Rosalyn Dang; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Sandra Spurlock; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD;	Novel Single-Agent Immunotherapies	Immune suppression; Myeloid cells; Metabolism; Solid tumors; T cell; Targeted therapy; Tumor evasion; Tumor microenvironment
P797	Novel dual A2A/A2B receptor antagonist reverses adenosine-mediated immune suppression - in vitro and in vivo characterization.	Michal Galezowski; Paulina Wegrzyn; Aneta Bobowska; Katarzyna Dziedzic; Magdalena Bonkowska; Karolina Grycuk; Joanna Szeremeta-Spisak; Marcin Nowogródzki; Grzegorz Satala; Alicja Obara; Iwona Lozinska-Raj; Przemyslaw Wyrebek; Marcelina Dudek; Anita Janiga; Jacek Reus; Marek Wronowski; Magdalena Zastawna; Grzegorz Statkiewicz; Maciej Rogacki; Mateusz Swirski; Jakub Woyciechowski; Kinga Michalik; Agnieszka Adamus; Karolina Wiatrowska; Natalia Literska; Aniela Golas; Olga Haberkiewicz; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Mateusz Nowak;	Novel Single-Agent Immunotherapies	Checkpoint blockade; Immune suppression; Inflammation; Metabolism; Tumor evasion; Tumor microenvironment
P816	DRP-104 Induces Durable Responses In Vivo by Inhibiting Tumor Glutamine Addiction, Remodeling the Tumor Microenvironment and Stimulating Both the Innate & Adaptive Immune Systems	Yumi Yokoyama, PhD; Michael Nedelcovych, PhD; Robert Wild, PhD;	Novel Single-Agent Immunotherapies	Cytokine; Monocyte/Macrophage; Metabolism; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P845	Targeting of Lactate Dehydrogenase C and its effects on the tumor immune microenvironment: two birds with one stone	Adviti Naik, PhD; Julie Decock, PhD; Aljazi M. Al-Khalifa;	Tumor and Stromal Cell Biology	Carcinogenesis; Cytokine; Gene expression; Immune contexture; Immune suppression; Metabolism; Solid tumors; Tumor antigens; Tumor evasion; Tumor microenvironment
P850	Metabolically reprogram MDSCs by targeting Pim kinases to overcome resistance to PD-1 blockade immunotherapy	Gang Xin; Yao Chen; Paytsar Topchyan; Aimin Jiang, PhD; Yiliang Chen; Roy Silverstein; Weiguo Cui; Gang Xin;	Checkpoint Blockade Therapy	Checkpoint blockade; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Metabolism; Solid tumors; Tumor microenvironment
Late-Breaking
P852	Transcriptomic analysis of dysfunctional CD8+ TILs in melanoma identifies bile acid and MTOR pathways as novel potential immunotherapy targets	Cheryl Cameron, PhD, Brian Richardson, Jackelyn Golden, Lukas Pfannensttiel, Michael Cartwright, Yousef Moustafa, Samjhana Thapaliya, Gustavo Roversi, Yee Peng Phoon, Mark Cameron, Brian Gastman, MD, Cheryl Cameron, PhD	Biomarkers, Immune Monitoring, and Novel Technologies	Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P853	Single Cell transcriptome analysis identifies unique features in circulating CD8+ T cells that can predict immunotherapy response in melanoma patients	Chuan Li, Yee Peng Phoon, Keaton Karlinsey, Ye Tian, Samjhana Thapaliya, Lili Qu, Mark Cameron, Cheryl Cameron, PhD, Antoine Menoret, Pauline Funchain, MD, Jung-Min Song, RN, CNS, C. Marcela Diaz-Montero, Annabelle Rodriguez, Christopher Bonin, Anthony Vella, Beiyan Zhou, Brian Gastman, MD	Biomarkers, Immune Monitoring, and Novel Technologies	Bioinformatics; Biomarkers; Checkpoint blockade; Gene expression; Immune suppression; Immune tolerance; Metabolism; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment